Enovis Future Growth
Future criteria checks 4/6
Enovis is forecast to grow earnings and revenue by 106.2% and 9.5% per annum respectively. EPS is expected to grow by 58.5% per annum. Return on equity is forecast to be 5.8% in 3 years.
Key information
106.2%
Earnings growth rate
58.5%
EPS growth rate
Medical Equipment earnings growth | 16.1% |
Revenue growth rate | 9.5% |
Future return on equity | 5.8% |
Analyst coverage | Good |
Last updated | 03 May 2024 |
Recent future growth updates
Recent updates
Enovis: Solid Growth, But Unstable Financial Footing
May 05Enovis Corporation (NYSE:ENOV) Might Not Be As Mispriced As It Looks
Apr 22Estimating The Intrinsic Value Of Enovis Corporation (NYSE:ENOV)
Feb 12Is Enovis (NYSE:ENOV) Using Too Much Debt?
Jan 14Investors Holding Back On Enovis Corporation (NYSE:ENOV)
Dec 18Calculating The Fair Value Of Enovis Corporation (NYSE:ENOV)
Nov 05Enovis Making Good Choices, But Not Seeing The Rewards
Sep 27Is Enovis (NYSE:ENOV) A Risky Investment?
Sep 22Estimating The Intrinsic Value Of Enovis Corporation (NYSE:ENOV)
Aug 03Enovis Corporation: Things Are Looking Good As Guidance Is Raised
Jul 18We Think Enovis (NYSE:ENOV) Has A Fair Chunk Of Debt
Jun 20Enovis Corporation Q4 2022 Earnings Preview
Feb 22Is Enovis (NYSE:ENOV) A Risky Investment?
Feb 22Is Enovis Corporation (NYSE:ENOV) Worth US$60.5 Based On Its Intrinsic Value?
Jan 25Enovis Corporation reports Q3 earnings beat; updates FY22 guidance
Nov 02Is Enovis (NYSE:ENOV) A Risky Investment?
Oct 19Is Enovis Corporation (NYSE:ENOV) Trading At A 27% Discount?
Sep 14Enovis launches augmented reality system ARVIS for use in hip, knee surgery
Jul 19Here's Why Enovis (NYSE:ENOV) Can Manage Its Debt Responsibly
Jul 05Enovis announces CFO transition
Jun 30Enovis: Medtech Leftover Of Colfax With Some To Prove
May 23As The Colfax Chapter Ends, Both ESAB And Enovis Have Something To Prove
Apr 05Is Colfax (NYSE:CFX) Using Too Much Debt?
Feb 20With EPS Growth And More, Colfax (NYSE:CFX) Is Interesting
Jan 05Colfax - Thoughts Ahead Of The Spin-Off
Jan 04Colfax Corporation (NYSE:CFX) Shares Could Be 32% Below Their Intrinsic Value Estimate
Dec 21Is Colfax (NYSE:CFX) Using Too Much Debt?
Nov 21Do Colfax's (NYSE:CFX) Earnings Warrant Your Attention?
Sep 30Is There An Opportunity With Colfax Corporation's (NYSE:CFX) 29% Undervaluation?
Sep 13Colfax: Setup Turns Compelling Heading Into The Upcoming Separation Event
Aug 15Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 2,471 | 40 | 395 | 515 | 6 |
12/31/2025 | 2,282 | 47 | 146 | 284 | 10 |
12/31/2024 | 2,126 | -30 | 45 | 169 | 10 |
3/29/2024 | 1,817 | -103 | -37 | 91 | N/A |
12/31/2023 | 1,707 | -54 | 13 | 135 | N/A |
9/29/2023 | 1,661 | -112 | -100 | 31 | N/A |
6/30/2023 | 1,627 | -159 | -106 | 19 | N/A |
3/31/2023 | 1,594 | -23 | -146 | -34 | N/A |
12/31/2022 | 1,563 | -39 | -161 | -56 | N/A |
9/30/2022 | 1,553 | 1 | -23 | 76 | N/A |
7/1/2022 | 1,530 | 54 | 47 | 154 | N/A |
4/1/2022 | 1,491 | -109 | 154 | 257 | N/A |
12/31/2021 | 1,426 | -103 | 252 | 356 | N/A |
10/1/2021 | 1,855 | -48 | 282 | 389 | N/A |
7/2/2021 | 2,301 | -18 | 262 | 371 | N/A |
4/2/2021 | 2,565 | 21 | 222 | 330 | N/A |
12/31/2020 | 1,121 | -75 | 187 | 302 | N/A |
10/2/2020 | 3,131 | 53 | 132 | 238 | N/A |
7/3/2020 | 3,172 | 39 | 102 | 214 | N/A |
4/3/2020 | 3,460 | 42 | 127 | 259 | N/A |
12/31/2019 | 3,327 | 8 | 6 | 131 | N/A |
9/27/2019 | 3,014 | 10 | 62 | 191 | N/A |
6/28/2019 | 2,692 | 21 | 94 | 203 | N/A |
3/29/2019 | 2,344 | 66 | 74 | 157 | N/A |
12/31/2018 | 2,193 | 108 | 157 | 226 | N/A |
9/28/2018 | 2,492 | -115 | 133 | 205 | N/A |
6/29/2018 | 2,813 | -84 | 87 | 154 | N/A |
3/30/2018 | 3,100 | -92 | 108 | 176 | N/A |
12/31/2017 | 1,937 | 28 | N/A | 219 | N/A |
9/29/2017 | 3,239 | 154 | N/A | 260 | N/A |
6/30/2017 | 3,161 | 147 | N/A | 289 | N/A |
3/31/2017 | 3,043 | 151 | N/A | 272 | N/A |
12/31/2016 | 3,186 | 138 | N/A | 247 | N/A |
9/30/2016 | 3,435 | 144 | N/A | 254 | N/A |
7/1/2016 | 3,637 | 126 | N/A | 293 | N/A |
4/1/2016 | 3,933 | 138 | N/A | 321 | N/A |
12/31/2015 | 3,434 | 158 | N/A | 304 | N/A |
9/25/2015 | 4,112 | 204 | N/A | 336 | N/A |
6/26/2015 | 4,307 | 259 | N/A | 416 | N/A |
3/27/2015 | 4,481 | 397 | N/A | 451 | N/A |
12/31/2014 | 4,624 | 370 | N/A | 386 | N/A |
9/26/2014 | 4,589 | 322 | N/A | 377 | N/A |
6/27/2014 | 4,440 | 299 | N/A | 314 | N/A |
3/28/2014 | 4,314 | 160 | N/A | 309 | N/A |
12/31/2013 | 4,207 | 154 | N/A | 362 | N/A |
9/27/2013 | 4,063 | 137 | N/A | 352 | N/A |
6/28/2013 | 4,003 | 91 | N/A | 291 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ENOV is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).
Earnings vs Market: ENOV is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ENOV is expected to become profitable in the next 3 years.
Revenue vs Market: ENOV's revenue (9.5% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: ENOV's revenue (9.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ENOV's Return on Equity is forecast to be low in 3 years time (5.8%).